Literature DB >> 2159542

Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera.

B Frech1, U Zimber-Strobl, K O Suentzenich, O Pavlish, G M Lenoir, G W Bornkamm, N Mueller-Lantzsch.   

Abstract

The terminal proteins TP1 and TP2 are putative products of Epstein-Barr virus (EBV) genes expressed during the latent cycle of the virus. They are predicted to code for 53- and 40-kilodalton integral membrane proteins. We used the baculovirus Autographa californica nuclear polyhedrosis virus as an expression vector to produce TP1 in large amounts in insect cells. The DNA sequences used to express TP1 originated from a TP1 cDNA derived from an M-ABA/CBL1 cDNA library. Rabbit antisera raised against procaryotic TP1 fusion proteins recognized a monomer and a dimer of the recombinant TP1 protein in the infected insect cells. Immunofluorescence studies of living insect cells showed that the recombinant protein is located in the plasma membrane. The insect cells infected with the recombinant baculovirus producing TP1 provided a test system to screen human antisera for TP1 antibodies. A total of 168 human EBV-positive and EBV-negative antisera were studied. TP1 antibodies were detected only in sera from nasopharyngeal carcinoma patients (16 out of 42). Rabbit antiserum raised against the recombinant TP1 protein expressed in the baculovirus system specifically recognized a protein of about 54 kilodaltons in the lymphoblastoid cell lines M-ABA and M-ABA/CBL1 and in the Burkitt's lymphoma cell lines BL18 and BL72. This protein could be located in the total membrane fraction of M-ABA cells and is upregulated by treating the cells with 12-O-tetradecanoylphorbol-13-acetate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159542      PMCID: PMC249456          DOI: 10.1128/JVI.64.6.2759-2767.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis.

Authors:  B C Strnad; T C Schuster; R F Hopkins; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

2.  A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection.

Authors:  L M Albritton; L Tseng; D Scadden; J M Cunningham
Journal:  Cell       Date:  1989-05-19       Impact factor: 41.582

3.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

4.  A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates.

Authors:  A Polack; G Hartl; U Zimber; U K Freese; G Laux; K Takaki; B Hohn; L Gissmann; G W Bornkamm
Journal:  Gene       Date:  1984-03       Impact factor: 3.688

5.  Analysis of adenovirus transforming proteins from early regions 1A and 1B with antisera to inducible fusion antigens produced in Escherichia coli.

Authors:  K R Spindler; D S Rosser; A J Berk
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

6.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

7.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

8.  Production of human beta interferon in insect cells infected with a baculovirus expression vector.

Authors:  G E Smith; M D Summers; M J Fraser
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

9.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

10.  Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro.

Authors:  A Henderson; S Ripley; M Heller; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

View more
  25 in total

1.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.

Authors:  A L Burkhardt; J B Bolen; E Kieff; R Longnecker
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma.

Authors:  P Busson; R McCoy; R Sadler; K Gilligan; T Tursz; N Raab-Traub
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  Biochemical characterization of Epstein-Barr virus nuclear antigen 2A.

Authors:  F A Grässer; P Haiss; S Göttel; N Mueller-Lantzsch
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

Authors:  S Fruehling; S K Lee; R Herrold; B Frech; G Laux; E Kremmer; F A Grässer; R Longnecker
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.

Authors:  C L Miller; J H Lee; E Kieff; R Longnecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

9.  Expression of the HIV-1 Nef protein in the baculovirus system: investigation of anti-Nef antibodies response in human sera and subcellular localization of Nef.

Authors:  N Kienzle; M Enders; M Buck; H Siakkou; S Jahn; G Petzold; K E Schneweis; M Bachmann; W E Müller; N Müller-Lantzsch
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome.

Authors:  Roland Hutzinger; Regina Feederle; Jan Mrazek; Natalia Schiefermeier; Piotr J Balwierz; Mihaela Zavolan; Norbert Polacek; Henri-Jacques Delecluse; Alexander Hüttenhofer
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.